Measles virus: Improving natural oncolytic properties by genetic engineering

Viral Therapy of Human Cancers

Volumn , Issue , 2004, Pages 459-480

  Springfeld, Christoph ^a   Fielding, Adele ^a   Peng, Kah Whye ^a   Galanis, Eva ^a   Russell, Stephen J ^a   Cattaneo, Roberto ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85058319483     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (82)

1. Katz M. Clinical spectrum of measles. Curr Top Microbiol Immunol 1995; 191:1-12.
2. Griffin DE. Measles Virus. In: David M. Knipe PMH, Eds Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2001: 1401-1442.
3. WHO. Global measles mortality reduction and regional elimination, 2000-2001. Part I. Wkly Epidemiol Rec 2002; 77:49-56.
4. Billeter MA, Cattaneo R, Spielhofer P, Kaelin K, Huber M, Schmid A, Baczko K, ter Meulen V. Generation and properties of measles virus mutations typically associated with subacute sclerosing panencephalitis. Ann N Y Acad Sci 1994; 724: 367-377.
5. Enders JF, Peebles TC. Propagation in tissue culture of cyto- pathogenic agents from patients with measles. Proc Soc Exp Biol Med 1954; 86:277-286.
6. Hilleman MR, Buynak EB, Weibel RE, Stokes J, Jr., Whitman JE, Jr., Leagus MB. Development and evaluation of the Moraten measles virus vaccine. Jama 1968; 206:587-590.
7. Duclos P, Ward BJ. Measles vaccines: a review of adverse events. Drug Saf 1998; 19:435-454.
8. Moss WJ, Cutts F, Griffin DE. Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin Infect Dis 1999; 29:106-112.
9. Sinkovics J, Horvath J. New developments in the virus therapy of cancer: a historical review. Intervirology 1993; 36:193-214.
10. Herná ndez SA. Observaciόn de un caso de enfermedad de Hodg- kin, con regresiόn de los s´?ntomas e infartos ganglionares, post- sarampiόn. Archivos Cubanos de Cancerologia 1949; 8:26-31.
11. Bluming AZ, Ziegler JL. Regression of Burkitt’s lymphoma in association with measles infection. Lancet 1971; 2:105-106.
12. Zygiert Z. Hodgkin’s disease: remissions after measles. Lancet 1971; 1:593.
13. Mota HC. Infantile Hodgkin’s disease: remission after measles. Br Med J 1973; 2:421.
14. Pasquinucci G. Possible effect of measles on leukaemia. Lancet 1971; 1:136.
15. Gross S. Measles and leukaemia Lancet 1971; 1:397-398.
16. Bellini WJ, Englund G, Rozenblatt S, Arnheiter H, Richardson CD. Measles virus P gene codes for two proteins. J Virol 1985; 53:908-919.
17. Cattaneo R, Kaelin K, Baczko K, Billeter MA. Measles virus editing provides an additional cysteine-rich protein. Cell 1989; 56:759-764.
18. Cathomen T, Naim HY, Cattaneo R. Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion compe- tence. J Virol 1998; 72:1224-1234.
19. Rager M, Vongpunsawad S, Duprex WP, Cattaneo R. Polyploid measles virus with hexameric genome length. EMBO J 2002; 21:2364-2372.
20. Simon EH. The distribution and significance of multiploid virus particles. Prog Med Virol 1972; 14:36-67.
21. Cattaneo R, Rebmann G, Schmid A, Baczko K, ter Meulen V, Billeter MA. Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J 1987; 6:681-688.
22. Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, Rabourdin-Combe C, Gerlier D. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 1993; 67:6025-6032.
23. Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993; 75:295-305.
24. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000; 406:893-897.
25. Schneider U, von Messling V, Devaux P, Cattaneo R. Efficiency of measles virus entry and dissemination through different receptors. J Virol 2002; 76:7460-7467.
26. Oldstone MB, Homann D, Lewicki H, Stevenson D. One, two, or three step: measles virus receptor dance. Virology 2002; 299: 162-163.
27. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dotsch C, Christiansen G, Billeter MA. Rescue of measles vi- ruses from cloned DNA. EMBO J 1995; 14:5773-5784.
28. Schneider H, Spielhofer P, Kaelin K, Dotsch C, Radecke F, Sut- ter G, Billeter MA. Rescue of measles virus using a replication- deficient vaccinia-T7 vector. J Virol Methods 1997; 64:57-64.
29. Takeda M, Takeuchi K, Miyajima N, Kobune F, Ami Y, Nagata N, Suzaki Y, Nagai Y, Tashiro M. Recovery of pathogenic mea- sles virus from cloned cDNA. J Virol 2000; 74:6643-6647.
30. Cathomen T, Mrkic B, Spehner D, Drillien R, Naef R, Pavlovic J, Aguzzi A, Billeter MA, Cattaneo R. A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain. EMBO J 1998; 17:3899-3908.
31. Escoffier C, Manie S, Vincent S, Muller CP, Billeter M, Gerlier D. Nonstructural C protein is required for efficient measles virus replication in human peripheral blood cells. J Virol 1999; 73:1695-1698.
32. Tober C, Seufert M, Schneider H, Billeter MA, Johnston IC, Niewiesk S, ter Meulen V, Schneider-Schaulies S. Expression of measles virus V protein is associated with pathogenicity and control of viral RNA synthesis. J Virol 1998; 72:8124-8132.
33. Mrkic B, Odermatt B, Klein MA, Billeter MA, Pavlovic J, Catta- neo R. Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice. J Virol 2000; 74:1364-1372.
34. Duprex WP, Duffy I, McQuaid S, Hamill L, Cosby SL, Billeter MA, Schneider-Schaulies J, ter Meulen V, Rima BK. The H gene of rodent brain-adapted measles virus confers neuroviru-lence to the Edmonston vaccine strain. J Virol 1999; 73: 6916-6922.
35. Johnston IC, ter Meulen V, Schneider-Schaulies J, Schneider- Schaulies S. A recombinant measles vaccine virus expressing wild-type glycoproteins: consequences for viral spread and cell tropism. J Virol 1999; 73:6903-6915.
36. Takeuchi K, Takeda M, Miyajima N, Kobune F, Tanabayashi K, Tashiro M. Recombinant wild-type and edmonston strain measles viruses bearing heterologous H proteins: role of H pro- tein in cell fusion and host cell specificity. J Virol 2002; 76: 4891-4900.
37. Maisner A, Mrkic B, Herrler G, Moll M, Billeter MA, Cattaneo R, Klenk HD. Recombinant measles virus requiring an exoge- nous protease for activation of infectivity. J Gen Virol 2000; 81: 441-449.
38. Moeller K, Duffy I, Duprex P, Rima B, Beschorner R, Fauser S, Meyermann R, Niewiesk S, ter Meulen V, Schneider-Schau- lies J. Recombinant measles viruses expressing altered hemag- glutinin (H) genes: functional separation of mutations determining H antibody escape from neurovirulence. J Virol 2001; 75:7612-7620.
39. Duprex WP, McQuaid S, Hangartner L, Billeter MA, Rima BK. Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombi- nant virus. J Virol 1999; 73:9568-9575.
40. Mrkic B, Pavlovic J, Rulicke T, Volpe P, Buchholz CJ, Hourcade D, Atkinson JP, Aguzzi A, Cattaneo R. Measles virus spread and pathogenesis in genetically modified mice. J Virol 1998; 72:7420-7427.
41. Neumeister C, Nanan R, Cornu T, Luder C, ter Muelen V, Naim H, Niewiesk S. Measles virus and canine distemper virus target proteins into a TAP- independent MHC class I-restricted anti- gen-processing pathway. J Gen Virol 2001; 82:441-447.
42. Grote D, Russell SJ, Cornu TI, Cattaneo R, Poland GA, Fielding AK. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001; 97: 3746-3754.
43. Peng KW, Facteau S, Wegman T, O’Kane D, Russell SJ. Noninvasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 2002; 8:527-531.
44. Singh M, Cattaneo R, Billeter MA. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol 1999; 73:4823-4828.
45. Wang Z, Hangartner L, Cornu TI, Martin LR, Zuniga A, Billeter MA, Nain HY. Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency vi- ruses. Vaccine 2001; 19:2329-2336.
46. Singh M, Billeter MA. A recombinant measles virus expressing biologically active human interleukin-12. J Gen Virol 1999; 80: 101-106.
47. Grote D, Cattaneo R, Fielding AK. Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res 2003; 63:6463-6468.
48. Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Rus- sell SJ. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001; 98:2002-2007.
49. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51:15-36.
50. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002; 62:4656-4662.
51. Peng KW, Frenzke M, Myers R, Soeffker D, Harvey M, Greiner S, Galanis E, Cattaneo R, Federspiel MJ, Russell SJ. Biodistri- bution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. Hum Gene Ther 2003; 14:1565-1577.
52. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK, Macura SI, Russell SJ, Galanis EC. Use of a vaccine strain of measles virus genetically engineered to pro- duce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003; 63: 2462-2469.
53. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 2001; 7:781-787.
54. Ring CJ. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83:491-502.
55. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent ade- novirus (ARCA) CN706: a selective cytotoxic for prostate-spe- cific antigen-positive prostate cancer cells. Cancer Res 1997; 57:2559-2563.
56. Hammond AL, Plemper RK, Cattaneo R. Targeting Measles Virus Entry. In: Curiel DT, Douglas JT, Eds. Vector Targeting for Therapeutic Gene Delivery. Hoboken: Wiley-Liss Inc., 2002: 321-336.
57. Schneider U, Bullough F, Vongpunsawad S, Russell SJ, Catta- neo R. Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol 2000; 74:9928-9936.
58. Hammond AL, Plemper RK, Zhang J, Schneider U, Russell SJ, Cattaneo R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carci- noembryonic antigen. J Virol 2001; 75:2087-2096.
59. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9:67-81.
60. Peng KW, Donovan KA, Schneider U, Cattaneo R, Lust JA, Russell SJ. Oncolytic measles viruses displaying a single chain antibody against CD38, a myeloma cell marker. Blood 2003: 101.
61. Bucheit AD, Kumar S, Grote DM, Lin Y, von Messling V, Catta- neo RB, Fielding AK. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 2003; 7:62-72.
62. Lecouturier V, Fayolle J, Caballero M, Carabana J, Celma ML, Fernandez-Munoz R, Wild TF, Buckland R. Identification of two amino acids in the hemagglutinin glycoprotein of measles virus (MV) that govern hemadsorption, HeLa cell fusion, and CD46 downregulation: phenotypic markers that differentiate vaccine and wild-type MV strains. J Virol 1996; 70:4200-4204.
63. Vongpunsawad S, Oezgun N, Braun W, Cattaneo R. Selectively receptor-blind measles viruses: Identification of residues neces- sary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol 2004; 78: 302-313.
64. Hermiston TW, Kuhn I. Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 2002; 9:1022-1035.
65. Springer CJ, Niculescu-Duvaz I. Prodrug-activating systems in suicide gene therapy. J Clin Invest 2000; 105:116-1167.
66. Parks GD, Young VA, Koumenis C, Wansley EK, Layer JL, Cooke KM. Controlled cell killing by a recombinant nonseg- mented negative-strand RNA virus. Virology 2002; 293: 192-203.
67. Fernandez M, Porosnicu M, Markovic D, Barber GN. Genetically engineered vesicular stomatitis virus in gene therapy: ap- plication for treatment of malignant disease. J Virol 2002; 76: 895-904.
68. Spitzweg C, Morris JC. The sodium iodide symporter: its patho- physiological and therapeutic implications. Clin Endocrinol (Oxf) 2002; 57:559-574.
69. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338:297-306.
70. Mandell RB, Mandell LZ, Link CJ, Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999; 59:661-668.
71. Cho JY, Shen DH, Yang W, Williams B, Buckwalter TL, La Perle KM, Hinkle G, Pozderac R, Kloos R, Nagaraja HN, Barth RF, Jhiang SM. In vivo imaging and radioiodine therapy follow- ing sodium iodide symporter gene transfer in animal model of intracerebral gliomas. Gene Ther 2002; 9:1139-1145.
72. Boland A, Ricard M, Opolon P, Bidart JM, Yeh P, Filetti S, Schlumberger M, Perricaudet M. Adenovirus-mediated trans- fer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000; 60:3484-3492.
73. Dingli D, Peng KW, Harvey ME, Greipp PR, O’Connor MK, Cattaneo R, Morris JC, Russell SJ. Image-guided radiovirother- apy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103:1641-1646.
74. Russell SJ. RNA viruses as virotherapy agents. Cancer Gene Ther 2002; 9:961-966.
75. Pedersen IR, Mordhorst CH, Glikmann G, von Magnus H. Sub- clinical measles infection in vaccinated seropositive individuals in arctic Greenland. Vaccine 1989; 7:345-348.
76. Muller CP, Huiss S, Schneider F. Secondary immune responses in parents of children with recent measles. Lancet 1996; 348: 1379-1380.
77. Damien B, Huiss S, Schneider F, Muller CP. Estimated suscep- tibility to asymptomatic secondary immune response against measles in late convalescent and vaccinated persons. J Med Virol 1998; 56:85-90.
78. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332-1334.
79. Heise C, Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000; 105:847-851.
80. Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Hers- cowitz HB, Martuza RL. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replica- tion-competent herpes simplex virus. Hum Gene Ther 1999; 10: 2741-2755.
81. Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thomp- son BG, Yoon CS, Waisman DM, Lee PW. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003; 63:348-353.
82. Tidona CA, Kurz HW, Gelderblom HR, Darai G. Isolation and molecular characterization of a novel cytopathogenic para- myxovirus from tree shrews. Virology 1999; 258:425-434.